Welcome to our dedicated page for Abvc Biopharma SEC filings (Ticker: ABVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating trial updates, dilution warnings, or insider buys inside ABVC BioPharma’s dense disclosures can feel like navigating lab notes written for regulators, not investors. 10-K risk factors span drug-specific toxicology, while 8-K material event notices often signal new licensing deals hours before headlines. That complexity is exactly why our platform exists.
Stock Titan delivers AI-powered summaries that turn every ABVC SEC document into plain-English insights. Need the latest ABVC quarterly earnings report 10-Q filing decoded? Our engine highlights R&D spend and cash runway in seconds. Want ABVC Form 4 insider transactions real-time? Instant alerts flag each executive stock move. From an ABVC annual report 10-K simplified to an ABVC proxy statement executive compensation, every filing type—10-K, 10-Q, 8-K, S-1, SC 13G—is indexed the moment it hits EDGAR and paired with context only biotech specialists usually notice.
Here’s how professionals use the page:
- Track ABVC insider trading Form 4 transactions before clinical data drops
- Compare trial spending quarter-over-quarter with our ABVC earnings report filing analysis
- Receive push notifications when an ABVC 8-K material events explained filing reveals a new collaboration
- Save hours understanding ABVC SEC documents with AI instead of reading hundreds of pages
- Monitor ABVC executive stock transactions Form 4 for buying and selling patterns
Whether you’re a portfolio manager scanning for catalyst dates or a researcher dissecting botanical drug data, our real-time feed and expert commentary ensure ABVC SEC filings explained simply—so you can focus on decisions, not document searches.
ABVC BioPharma received an amended Schedule 13G filed by Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton reporting beneficial ownership of 557,143 shares, equal to 3.2% of the outstanding common stock. The position is composed of 0 currently held common shares, 500,000 B Warrants and 57,143 shares issuable under convertible securities. Lind Global Partners II LLC and Mr. Easton report sole voting and dispositive power over the position.
The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
ABVC BioPharma has filed a Form S-8 registration statement to register an additional 2,515,989 shares of common stock under its Second Amended and Restated 2016 Equity Incentive Plan. The company's authorized capital consists of 100 million shares of common stock and 20 million shares of preferred stock, both with $0.001 par value.
Key details:
- Currently has 16,773,261 shares of common stock outstanding
- No preferred stock currently outstanding
- Classified as a non-accelerated filer and smaller reporting company
- Led by CEO Dr. Uttam Patil, who also serves as Interim CFO
The filing includes comprehensive indemnification provisions for directors and officers under Nevada law (NRS 78.138), protecting them against liability except in cases of intentional misconduct, fraud, or knowing violations of law. The registration statement incorporates by reference various SEC filings from 2025, including annual, quarterly, and current reports.
FAQ
What is the current stock price of Abvc Biopharma (ABVC)?
What is the market cap of Abvc Biopharma (ABVC)?
